SYNGENTA CORPORATION for SYNGENTA CORPORATION
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 19, 2011 | $110,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Jun 4, 2012 | $210,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Agriculture AGR
Agriculture appropriations; Biofuels, Farm Bill; Biotechnology and Pesticides; Patent Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANGUS KELLY | — |
Trade (domestic/foreign) TRD
Trade issues; Duty suspension; Biotechnology.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANGUS KELLY | — |
Copyright/Patent/Trademark CPT
Patent bill numbers S23 adn HR1249.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANGUS KELLY | — |
Food Industry (safety, labeling, etc.) FOO
Biotechnology and biotech product issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANGUS KELLY | — |
Tariff (miscellaneous tariff bills) TAR
Duty suspension regarding the following: 1) Product: Difenoconazole, House Bill: HR 4794; 2) Product: DCDNBTF Benzene, House Bill: HR 4803; 3) Product: 2-Chloro-6- Fluorobenzyl, House Bill: HR 4805; 4)Product: Flumetralin Technical, House BIll: HR 4802; 5) Cyprodinil Tech, House Bill: HR 4793; 6) Product: Trinexapac-Ethyl Tech, House Bill: HR 4801; 7) Product: Lamda-Cyhalothrin, House Bill: HR 4797; 8) Product: Thia-Difen-Flud-Mef, House Bill: HR 4796; 9) Product: Difenoconazole & Mefenoxem, House Bill: HR 4795; 10) Product: Mucochloric Acid, House Bill: HR 4798; 11) Methidathion Tech, House Bill: HR 4800; 12) 4-Chloro-3.5 Dinitrobenzotrifluoride, House Bill: HR 4804; 13) Wakil XL, House Bill: HR 4799; 14) Thiamethoxam Tech, House Bill: HR 4728; 15) Trifloxysulfuron-Sodium Tech, House Bill: HR 4730; 16) Triasulfuron Tech, House Bill: HR 4729; 17) Propiconazole Tech; 18) Paraquat Dechloride Tech, House Bill: HR 4642; 19) NOA 446510 Tech, House Bill: HR 4639; 20) IPN, House Bill: HR 4640; 21) Paclobutrazol 2SC, House Bill: HR 4643; 22) Paclobutrazol Tech, House Bill: HR 4638; 23) Brodifacoum Tech, House Bill: HR 4644; 24) Azoxystrobin Technical-benzeneacertic; 25) Fludioxinil Tech, House Bill: HR 4711; 26) Clodinafop Tech; House Bill: HR 4712; 27) Pinoxaden Tech; House Bill: HR 4715; 28) Azoxystrobin Technical; House Bill: HR 4792; 29) Mefenoxam Tech; House Bill: HR 4714; 30) TEHP; 31) Cloquintocet Tech; House BIll: HR 4709; 32) Prosulfuron Tech; House Bill: HR 4717; 33) Avermectin B; House Bill: HR 4708; 34) Cyproconazole Tech, House Bill: HR 4710; 35) Pymetrozine Tech, House Bill: HR 4718; 36) Primisulfuron; 37) Mesotrione Tech, House Bill: HR 4366; 38) s-Metolachlor; 39) DEMBB -Bromo, House Bill: HR 4365; 40) Promdiamine Tech, House Bill: HR 4572; 41) Chloroacetone, House Bill: HR 4641; 42) Ortho-Nitro-Phenol 2-Nitrophenol, House Bill: HR 4573.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANGUS KELLY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.